• 1
    Poynard T, Marcellin P, Lee S S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) [see comments]. Lancet 1998; 352 (9138): 142632.
  • 2
    McHutchison J G, Gordon S C, Schiff E R, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998; 339 (21): 148592.
  • 3
    Reichard O, Norkrans G, Fryden A, Braconier J H, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group [see comments]. Lancet 1998; 351 (9096): 837.
  • 4
    Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski J P. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 1996; 41 (12 Suppl.): 99S102S.
  • 5
    Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group [see comments] [published erratum appears in N Engl J Med 1996 Apr 25; 334(17): 1143]. N Engl J Med 1995; 332 (22): 145762.
  • 6
    Poynard T, Leroy V, Cohard M, Mathurin P, Opolon P, Zarski J. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 1995; 22 (4 pt 2): 113A.
  • 7
    Hadziyannis A S, Papaioannou C, Spanou F, Manesis E K, Hadziyannis S J. Induction interferon therapy in naive patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther 2001; 15 (4): 5517.
  • 8
    Heathcote E J, Shiffman M L, Cooksley W G, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343 (23): 167380.
  • 9
    Manns M P, McHutchison J G, Gordon S C, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 95865.
  • 10
    Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 97582.
  • 11
    Hadziyannis S, Cheinquer H, Morgan T, et al. Peginterferon alpha-2a (40kd) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. Hepatology 2002; 36(S1): 3.
  • 12
    Weiland O. Chronic viral hepatitis: understanding and managing resistance to treatment: prevention and treatment of HCV resistance. In: FerenciP, ed. EASL Postgraduate Course. Istanbul, Turkey: Kenes International, 2003; 11522.
  • 13
    Zeuzem S, Schmidt J M, Lee J-H, Ruster B, Roth W K. Effect of interferon alpha of the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 36671.
  • 14
    Lam N P, Neumann A U, Gretch D R, Wiley T E, Perelson A S, Layden T J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26 (1): 22631.
  • 15
    Neumann A U, Lam N P, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182 (1): 2835.
  • 16
    Zeuzem S, Herrmann E, Lee J H, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120 (6): 143847.
  • 17
    Levrero M. Cellular mechanisms of resistance to IFNS. In: FerenceP, ed. Chronic Viral Hepatitis: Understanding and Managing Resistance to Treatment. Istanbul, Turkey: Kenes International, 2003.
  • 18
    Zeuzem S, Schmidt J M, Lee J H, Von Wagner M, Teuber G, Roth W K. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology 1998; 28 (1): 24552.
  • 19
    Layden T J. Principles of interferon induction therapy. Am J Med 1999; 107 (6B): 71S3S.
  • 20
    Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55 (4): 3607.